Jim Cramer Rejects UiPath Despite Cheap Valuation, Backs Affirm
Cramer called UiPath cheap but lacking catalysts, endorsed Karman and Affirm, warned on Onto and Nio, and favored Regeneron, Vertex and Amgen over Alnylam
Last updated: 2026-11-20 21:35:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Vertex Pharmaceuticals Inc. (VRTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $515.19, with a market capitalization of $136.01B and a P/E ratio of 34.21. Over the past 52 weeks, its price has ranged from $412.27 to $568.67. This page covers its latest market performance, valuation, price trends and company information.
$136.01B | |
$529.94 | |
$531.46 | |
$514.05 | |
$520.66 | |
1.22M | |
1.24M | |
34.21 | |
$568.67 | |
$412.27 | |
-- | |
2026-09-30 |
Vertex Pharmaceuticals Inc. (VRTX) is trading at $521.00 in after-hours trading as of 2026-11-20 21:31:00, up 1.13% ($5.81) from the regular-session close of $515.19.
After-hours trading shows how investors are pricing VRTX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Vertex Pharmaceuticals Inc. (VRTX) moved from $547.03 to $515.19, representing a decline of 5.82% ($31.84).
The stock traded between $514.05 and $552.27 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.15 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 65.8%
VRTX is currently trading at $515.19, placing it 65.8% of the way from its 52-week low of $412.27 to its 52-week high of $568.67. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6,400 |
| CEO | Reshma Kewalramani |
| Founded | 1989 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Vertex Pharmaceuticals Inc. and VRTX stock.
Cramer called UiPath cheap but lacking catalysts, endorsed Karman and Affirm, warned on Onto and Nio, and favored Regeneron, Vertex and Amgen over Alnylam
Vertex Pharmaceuticals and Regeneron Pharmaceuticals are recommended as strong growth stocks for November. Both biotech companies started 2026 slowly but have rebounded with above-average returns. Vertex is poised for approval of povetacicept for kidney disease and has a pipeline potentially worth $10 billion in annual sales. Regeneron is driven by blockbuster Dupixent sales (up 35% YoY) and is managing Eylea's decline with a newer HD formulation.
The article compares Johnson & Johnson and Vertex Pharmaceuticals as investment options for 2027. JNJ is a diversified healthcare giant with $99.3B in revenue and strong cash flow, while VRTX is a specialized biotech leader with $13B in revenue focused on cystic fibrosis and expanding into gene therapies. Despite VRTX's higher growth rate and lower P/E ratio, JNJ is recommended as the better buy due to its superior valuation multiples (P/E 25.4x vs 29.6x, P/S 6.8x vs 10.5x) and established market position.
Natera Inc. (NASDAQ:NTRA) short sellers added to their positions as of the latest settlement date.Short interest rose 3.77% to 6.07 million shares as of the Oct. 30 settlement date, from 5.85 million at the Oct. 15
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
Eligible investors can buy real shares of Vertex Pharmaceuticals Inc. (VRTX) through MEXC Stocks. Follow these three steps to open a Stocks account, transfer USDT, and place a Stocks order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to VRTX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between VRTX shares and USD.
VRTX Shares to USD
1.00 VRTX shares = 515.186 USD
Calculations are estimates based on the latest available price and are for reference only.